Adverts

Open Access Articles- Top Results for MMAI

International Journal of Innovative Research in Science, Engineering and Technology
UPFC for Enhancement of Angle Stability Using Optimization Technique
International Journal of Innovative Research in Science, Engineering and Technology
Control and Monitoring System For Liquefied Petroleum Gas (LPG) Detection
International Journal of Innovative Research in Computer and Communication Engineering
Digitalised Secure Information Channel Maintenance in Distributed Broking System
International Journal of Innovative Research in Computer and Communication Engineering
Multi Resolution Pruning Based Co-location Identification in Spatial Data
International Journal of Innovative Research in Computer and Communication Engineering
Decentralised Access Control with Aggregate Key Encyryption For Data Stored In Cloud

MMAI

</th></tr>
MMAI
File:5-methoxy-6-methyl-2-aminoindane.svg
Systematic (IUPAC) name
5-methoxy-6-methyl-2,3-dihydro-1H-inden-2-amine
Clinical data
  • Uncontrolled
Oral
Identifiers
132980-16-6
None
PubChem CID 131575
ChemSpider 116274
Chemical data
Formula C11H15NO
177.242 g/mol

5-Methoxy-6-methyl-2-aminoindane (MMAI), is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University.[1] It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) and produces entactogen effects in humans.[1][2][3] It has been sold as a designer drug and research chemical online since 2010.[4]

MMAI has been shown to relieve stress-induced depression in rats more robustly than sertraline,[5] and as a result it has been suggested that SSRAs like MMAI and 4-MTA could be developed as novel antidepressants with a faster onset of therapeutic action and superior efficacy to current antidepressants such as the selective serotonin reuptake inhibitors (SSRIs).[6]

See also

References

  1. ^ a b Marona-Lewicka D, Nichols DE. (1994). "Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan". Eur J Pharmacol. 258 (1-2): 1–13. PMID 7925587. doi:10.1016/0014-2999(94)90051-5. 
  2. ^ Li Q, Murakami I, Stall S, Levy AD, Brownfield MS, Nichols DE, Van de Kar LD. (1996). "Neuroendocrine pharmacology of three serotonin releasers: 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (MBDB), 5-methoxy-6-methyl-2-aminoindan (MMAi) and p-methylthioamphetamine (MTA)". J Pharmacol Exp Ther. 279 (3): 1261–1267. PMID 8968349. 
  3. ^ Rudnick G, Wall SC. (1993). "Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters". Mol Pharmacol. 43 (2): 271–276. PMID 8429828. 
  4. ^ "Latest Research Chemicals". 
  5. ^ Marona-Lewicka D, Nichols DE. (1997). "The Effect of Selective Serotonin Releasing Agents in the Chronic Mild Stress Model of Depression in Rats". Stress 2 (2): 91–100. PMID 9787258. doi:10.3109/10253899709014740. 
  6. ^ Neuropharmacology; Silveira, R; Nichols, DE; Reyes-Parada, M (1999). "Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action". Neuropharmacology 38 (7): 1055–1061. PMID 10428424. doi:10.1016/S0028-3908(99)00023-4.